Table 1.

Patient and donor characteristics


Characteristic

Data
Age, y, median (range)  18.6 (1.3-53.4)  
   No. patients younger than 20 y   47  
   No. patients 20 y or older   40  
No. male/no. female   50/37  
Ethnic origin, no. patients  
   White   61  
   Hispanic   13  
   African American   5  
   Asian   6  
   Unknown   2  
Disease duration, mo, median (range)   14.6 (3-328)  
Pretransplantation therapy  
   Transfusions, no. patients   87  
   Immunosuppression, no. patients   87  
      No. courses, median (range)   3 (1-11)* 
Donor age, y, median (range)   36 (18-58)  
Donor sex, no. male/no. female  51/34  
Donor/patient sex combination, no.  
   Female → female   21  
   Female → male   13  
   Male → male   35  
   Male → female   16  
CMV status, no. patients  
   D+–P+  21  
   D+–P  32  
   D–P  15  
   D–P+  5  
   Other  14  
Donor/patient HLA compatibility, no. patients  
   Identical   62  
   Nonidentical   25  
Marrow cell dose, × 108/kg, median (range)
 
3.1 (0.006-15.6)
 

Characteristic

Data
Age, y, median (range)  18.6 (1.3-53.4)  
   No. patients younger than 20 y   47  
   No. patients 20 y or older   40  
No. male/no. female   50/37  
Ethnic origin, no. patients  
   White   61  
   Hispanic   13  
   African American   5  
   Asian   6  
   Unknown   2  
Disease duration, mo, median (range)   14.6 (3-328)  
Pretransplantation therapy  
   Transfusions, no. patients   87  
   Immunosuppression, no. patients   87  
      No. courses, median (range)   3 (1-11)* 
Donor age, y, median (range)   36 (18-58)  
Donor sex, no. male/no. female  51/34  
Donor/patient sex combination, no.  
   Female → female   21  
   Female → male   13  
   Male → male   35  
   Male → female   16  
CMV status, no. patients  
   D+–P+  21  
   D+–P  32  
   D–P  15  
   D–P+  5  
   Other  14  
Donor/patient HLA compatibility, no. patients  
   Identical   62  
   Nonidentical   25  
Marrow cell dose, × 108/kg, median (range)
 
3.1 (0.006-15.6)
 

N = 87 patients.

P indicates patient; D, donor

*

Single agent or combination regimens, with or without hemopoietic growth factors

Unavailable in 2 donors

In 3 patients the test was indeterminate; in the remaining 11 patients the data were not available

Close Modal

or Create an Account

Close Modal
Close Modal